Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Role of Ghrelin in Cancer Cachexia
NCT01505764 · VA Office of Research and Development · PHASE2 · terminated · last registry update 2018-07-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “poor recruitment” | – | Registry record, VA Office of Research and Development |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GHSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-12-26Phase 3 first posted: Allergan, Relamorelin 10 μg (NCT03786380)
- 2018-11-15Phase 3 first posted: Helsinn Healthcare SA, anamorelin HCl + Placebo Oral Tablet (NCT03743064)
- 2018-11-15Phase 3 first posted: Helsinn Healthcare SA, Anamorelin Hydrochloride + Placebo Oral Tablet (NCT03743051)
- 2018-08-20Phase 3 first posted: M.D. Anderson Cancer Center, Anamorelin Hydrochloride (NCT03637816)
- 2018-05-14Also stopped (withdrawn): University of Virginia, MK-0677 + Placebo (NCT01343641)
- 2018-02-09Results posted on the registry: AEterna Zentaris, Macimorelin + Insulin (NCT02558829)
- 2018-02-08Phase 3 first posted: Allergan, Placebo + Relamorelin (NCT03426345)
- 2018-02-05Phase 3 first posted: Allergan, Placebo + Relamorelin (NCT03420781)
- 2017-12-26Phase 3 first posted: Allergan, Placebo + Relamorelin (NCT03383146)
- 2017-09-18Phase 3 first posted: Allergan, Placebo + Relamorelin (NCT03285308)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision